Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst
02:11pm, Wednesday, 11'th Mar 2026
Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc (NASDAQ: LGND), citing the distinctive royalty firm offers compelling upside.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
01:51pm, Wednesday, 11'th Mar 2026
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfo
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
09:49am, Wednesday, 11'th Mar 2026
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company’s...
Power Metallic Mines seen as undervalued as Lion Zone drilling delivers record copper grades
09:34am, Wednesday, 11'th Mar 2026
Noble Capital Markets believes that Power Metallic Mines Inc (TSX-V:PNPN, FRA:IVV1, OTCQB:PNPNF) may be underappreciated by the market, citing continued...
Pre-Market Stock Futures: Futures are trading lower as we hit the mid-point of the trading week, and while we didn't see the snapback rally that was the star of the show Monday, at least all four majo
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock
05:14am, Sunday, 08'th Mar 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the firm's stock in a transaction on Wednesday, March 4th. The shares were sold at an a
This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59%
12:47pm, Friday, 06'th Mar 2026
Solid pharma stocks offer promising upside opportunities. This particular play is eyeing an entry as earnings surge.
Ligand to Participate in March Investor Conferences
07:00am, Wednesday, 04'th Mar 2026
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
05:47pm, Thursday, 26'th Feb 2026
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Thursday, 26'th Feb 2026
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of
CenterBook Partners LP Has $1.14 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
04:07am, Saturday, 21'st Feb 2026
CenterBook Partners LP lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 52.2% during the third quarter, according to the company in its most recent filing with the
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
07:00am, Thursday, 12'th Feb 2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:00am, Wednesday, 04'th Feb 2026
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi
Acuitas Investments LLC Purchases 382,597 Shares of Ligand Pharmaceuticals Incorporated $LGND
03:02am, Friday, 30'th Jan 2026
Acuitas Investments LLC boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 1,922.9% in the third quarter, according to its most recent filing with the Securities a
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Chicago Capital LLC
04:33am, Tuesday, 06'th Jan 2026
Chicago Capital LLC lowered its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 0.6% in the third quarter, according to the company in its most recent filing with the SEC.
